| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.1 |
| Net income | -1.7 | -7.8 |
| EPS (diluted, $ a share) | $-0.24 | $-2.59 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -4.3% |
|---|
10-Q filed with the SEC, NASDAQ: CALC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CalciMedica, Inc.: key numbers
- Share price
- $1.19Close, Nov 16
- Market cap
- $8.21M
- Shares outstanding
- 6.9MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CalciMedica, Inc.
All →CalciMedica Financial Results
CalciMedica reported third quarter 2026 financial results, ending the period with $13.8 million in cash which is expected to fund operations into the second half of 2027. The company highlighted clinical progress in its pulmonary hypertension and acute pancreatitis programs, with Phase 1b data for Auxora expected in mid-2027. Additionally, the company completed a 1-for-5 reverse stock split in August 2026 to regain Nasdaq compliance.
- Term
- 3 years
“We continue to advance our pulmonary hypertension strategy, with data from the Auxora Phase 1b proof-of-concept trial in PH and the CM5480 IND submission both anticipated in mid-2027. Preclinical models suggest CRAC channel inhibitors may provide a differentiated approach in pulmonary hypertension by targeting multiple disease drivers, including right ventricular dysfunction, which is the principal cause of mortality and not directly targeted by existing therapies.”
Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica
CalciMedica Leadership Change
Stephen Bardin, the Chief Financial Officer, principal accounting officer, and principal financial officer of CalciMedica, Inc., has resigned to pursue another professional opportunity. The resignation is effective immediately following the filing of the company's Quarterly Report on Form 10-Q for the period ended September 30, 2026, and was not due to any disagreement with the company.
CalciMedica Other 8-K Filing
CalciMedica filed a prospectus supplement to establish an at-the-market (ATM) offering program for the sale of up to $25 million of its common stock. The sales may occur from time to time through H.C. Wainwright & Co. under an existing offering agreement. As of this filing, no shares have been sold and no proceeds have been received.
- Counterparty
- H.C. Wainwright & Co.
CalciMedica Nasdaq/NYSE Compliance Notice
CalciMedica has regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days. The company had previously received a deficiency notice on March 16, 2026, and now has no outstanding deficiency notices from the exchange.
- Counterparty
- Nasdaq